(Q28188666)

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

The catastrophic antiphospholipid syndrome 1996: acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Streptokinase in acute ischemic stroke: an individual patient data meta-analysis : The Thrombolysis in Acute Stroke Pooling Project

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin Mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Successful coronary stent implantation in a patient with primary antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

The management of thrombosis in the antiphospholipid-antibody syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Antiplatelet factor 4--heparin antibodies in patients with antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Monitoring warfarin therapy in patients with lupus anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Successful thromboendarterectomy for chronic pulmonary embolism in a patient with systemic lupus erythematosus and antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Hydroxychloroquine: past, present, future

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Cerebrovascular ischemic events with high positive anticardiolipin antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021

Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism: prevalence and association with recurrent thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970225-8

7 January 2021